Keywords: Medivation, Astellas, Enzalutamide, MDV3100, Prostate cancer

Medivation files NDA for prostate cancer drug enzalutamide

Article | 23 May 2012

Print This

US drug developer Medivation (Nasdaq: MDVN) says it has submitted a New Drug Application to the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in